Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06352723 · ClinicalTrials.gov registry record · Early Phase 1
Cenobamate in the Intensive Care Unit
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT06352723 is a Early Phase 1 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT06352723, a Early Phase 1 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH. Monitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome.
Interventions
- DRUG Cenobamate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06352723
The ClinicalTrials.gov registry entry for NCT06352723 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenobamate is the first listed.
NCT06352723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06352723 about?
NCT06352723 is a clinical study titled "Cenobamate in the Intensive Care Unit". The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its ...
What is the current status of trial NCT06352723?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT06352723?
The interventions under investigation include: Cenobamate (DRUG).
Who is sponsoring clinical trial NCT06352723?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.